Please activate JavaScript!
Please install Adobe Flash Player, click here for download

2013|14 Annual Report Fraunhofer IGB

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB Project Group “Regenerative Technologies in Oncology” c / o University Hospital of Würzburg Chair Tissue Engineering and Regenerative Medicine Röntgenring 11  |  97070 Würzburg  |  Germany Prof. Dr. Heike Walles Phone +49 931 31-88828 Fax +49 931 31-81068 heike.walles@igb.fraunhofer.de Contact Norway, Austria, and Australia. Clinical studies of these novel innovative ATMPs (Advanced Therapies Medicinal Products) are prepared in Germany, Austria, and Norway. The culture of our vascularized scaffold BioVaSc in specific bioreactors where we can also generate complex vascularized implants has now also been established under GMP conditions in cooperation with the University Hospital Würzburg. Under a BMBF-funded project, we are preparing first clinical studies for a trachea im- plant based on the BioVaSc. Our research services can be used for the entire value-added chain in the development of cancer therapies. Range of services Production and biochemical modification of tissue engi- neered electrospun 3D scaffolds Isolation of primary human stem and tumor cells Establishment of co-cultures for the generation of human solid tumors in vitro and tumor test systems Development of specific bioreactors for various tumor models Development of human vascularized tumor tissue for the establishment of individual diagnostics and personalized treatments Biological cell analysis of tumor tissue: molecular-biologi- cal, histological and immunohistochemical methods, flow cytometry (FACS) Target screening for new cancer therapeutics Value chain Investigation of the active principle and / ​or the side effects of new drug candidates utilizing vascularized human tu- mor test systems Use of the tumor model in the process development of optimizing drugs or diagnostics Implementation and validation of in vitro tests as alterna- tives to animal testing at the end of the preclinical devel- opment phase Efficacy experiments of new drugs that are currently un- dergoing evaluation for clinical use Cooperation with the Medical Faculty of the University Hospital of Würzburg for the organization of the clinical phases I – III Infrastructure and technical equipment Cell culture laboratories for work on safety levels S1 and S2 GenTSV (genetic engineering safety regulations) Cell analysis: Fluorescence microscope, FACS, microdissec- tion system, Raman spectroscopy 63

Overview